Coherus Oncology (CHRS) Payables (2013 - 2026)

Coherus Oncology has disclosed Payables across 14 years of filings, most recently posting $11.5 million for Q1 2026.

• Payables for Q1 2026 came in at $11.5 million, down 71.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (down 71.95% YoY), and the FY2025 annual result was $9.9 million, down 65.16% from the prior year.
• Payables came in at $11.5 million for Q1 2026 at Coherus Oncology, up from $9.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $76.8 million in Q2 2024 to a low of $9.9 million in Q4 2025.
• The 5-year median for Payables is $24.9 million (2025), against an average of $27.9 million.
• Across the five-year window, Payables tumbled 92.17% in 2022 and surged 274.02% in 2023, its largest moves.
• Coherus Oncology's Payables stood at $11.5 million in 2022, then jumped by 205.56% to $35.2 million in 2023, then fell by 19.2% to $28.5 million in 2024, then tumbled by 65.16% to $9.9 million in 2025, then advanced by 15.77% to $11.5 million in 2026.
• The last three Payables figures came in at $11.5 million (Q1 2026), $9.9 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.